LYNX LICENSES RESTENOSIS COMPOUND TO WELLCOME FOR UP TO $30 MIL.
LYNX LICENSES RESTENOSIS COMPOUND TO WELLCOME FOR UP TO $30 MIL. in an agreement signed Aug. 4. The agreement covers development and marketing rights for a synthetic antisense oligonucleotide developed by Hayward, Calif.-based Lynx Therapeutics for the treatment of restenosis. The oligonucleotide is "about to enter" human clinical trials. Lynx developed the oligonucleotide in collaboration with Thomas Jefferson University.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth